Chinese Herbal Medicine Benefits: What the Clinical Evidence Shows
target-keyword: chinese herbal medicine benefitsarticle-type: clinical-evidence-reviewupdated: 2026-09-08 00:00 America/New_Yorkcompany: EnerQi Wellness Inc.
Chinese herbal medicine (CHM) is a clinical system that uses combinations of medicinal substances selected according to an individual’s presentation. Current research has evaluated CHM for depression, multiple sclerosis (MS), menopausal vasomotor symptoms, pain, sleep disorders, and inflammatory conditions.
The evidence indicates potential benefit in several domains. The certainty of evidence varies by condition, formula, comparator, treatment duration, and trial quality. Chinese herbal medicine should not replace indicated medical treatment, disease-modifying therapy, antidepressants, hormone therapy, or oncology care without coordination with the responsible medical team.
What Chinese herbal medicine is
Chinese herbal medicine generally involves an individualized formula rather than a single-herb supplement. A practitioner assesses symptom patterns, medical history, sleep, digestion, energy, stress response, medications, and other clinical features before selecting a combination.
Common delivery formats include:
- Decoctions: Raw herbs simmered in water and taken as a liquid.
- Granules: Concentrated herbal extracts dissolved in warm water.
- Capsules or pills: Pre-formulated or practitioner-selected extracts.
- Powders: Dried preparations mixed with water or food as directed.
Clinical research often uses named formulas, such as Xiaoyao Powder or Chai Hu Shu Gan San. These formulas are not interchangeable with over-the-counter products containing one similarly named herb. Composition, dosage, extraction method, sourcing, and quality control can differ substantially.
Individualized care is also distinct from selecting a general “herbal remedy” for a symptom. At EnerQi Wellness, Chinese herbal medicine may be considered within a broader personalized care pathway, including acupuncture, lifestyle assessment, and coordination with existing medical care.
Depression: 2024 network meta-analysis
A 2024 systematic review and Bayesian network meta-analysis published in Frontiers in Pharmacology evaluated 198 randomized controlled trials involving 8,923 patients and 17 Chinese herbal medicines.
The analysis assessed:
- Hamilton Depression Rating Scale (HAMD) scores.
- Clinical response rates.
- Reported adverse events.
- Direct and indirect comparisons with antidepressant medications.
Several formulas demonstrated higher response rates or greater HAMD reductions than selected antidepressants within the evidence network. The formulas ranked most favorably for response rate included:
- Guipiwan.
- Ease Pill.
- Chaihu Jia Longgu Muli Decoction.
The formulas ranked most favorably for HAMD reduction included:
- Chai Hu Shu Gan San.
- Xingnao Jieyu Decoction.
- Xiaoyao Powder.
Xiaoyao Powder ranked highest for safety based on adverse-event outcomes in the included network. The analysis also reported lower adverse-event rates for several CHM formulas compared with selected antidepressants.
The findings require qualification. All included studies were conducted in China. Trial duration ranged from approximately four weeks to six months. Of the 198 RCTs, 135 were assessed as having “some concerns” regarding risk of bias, 28 were assessed as low risk, and 35 were assessed as high risk.
Bottom line: The 2024 network meta-analysis showed a clinically relevant signal for several formulas in depression, but small trials, geographic concentration, heterogeneous protocols, and risk of bias reduce certainty. The findings support further research rather than universal substitution of antidepressant treatment.
Multiple sclerosis: 2025 meta-analysis
A 2025 meta-analysis in Frontiers in Pharmacology assessed CHM combined with conventional therapy versus conventional therapy alone in multiple sclerosis. The review included 28 RCTs and 1,971 participants.
Reported outcomes included:
| Outcome | Reported result | Interpretation |
|---|---|---|
| Expanded Disability Status Scale | MD −0.65; 95% CI −0.96 to −0.35 | Lower disability score in the CHM combination group |
| Annualized relapse rate | RR 0.48; 95% CI 0.31 to 0.73 | Fewer relapses reported in the CHM combination group |
| Modified Fatigue Impact Scale | MD −8.55; 95% CI −10.20 to −6.89 | Lower fatigue impact score |
| Neurological signs score | MD −2.96; 95% CI −4.52 to −1.39 | Lower reported neurological symptom score |
No serious adverse events were reported in the included studies. The authors characterized the methodological quality as relatively suboptimal and called for better-designed trials.
The results do not establish CHM as a replacement for disease-modifying therapy or neurological management. MS treatment decisions require ongoing assessment by a neurologist. EnerQi’s published information on supportive care for MS similarly frames Chinese medicine as complementary to specialist care.
Bottom line: The 2025 meta-analysis showed improved disability, relapse, and fatigue outcomes when CHM was added to conventional therapy, but GRADE certainty ranged from moderate to very low. The findings are adjunctive and not disease-modifying treatment evidence.
Menopausal hot flushes: contrasting reviews
A 2019 systematic review and meta-analysis in PLOS ONE evaluated 19 RCTs involving 2,469 women with menopausal hot flushes.
Compared with placebo, CHM was associated with:
- Hot-flush severity: MD −0.70; 95% CI −1.00 to −0.40.
- Total Kupperman Index: MD −12.61; 95% CI −15.21 to −10.01.
- Hot-flush frequency: no statistically significant difference.
The review reported no significant hormone changes and described adverse events as generally mild, including gastrointestinal symptoms.
The conclusion differs from the 2016 Cochrane review of Chinese herbal medicines for menopausal symptoms. Cochrane found insufficient evidence that CHM was more or less effective than placebo or hormone therapy for vasomotor symptoms. The Cochrane analysis identified small sample sizes, inconsistent outcome measures, heterogeneous formulas, and methodological limitations.
This contrast demonstrates why a single positive meta-analysis should not be interpreted as definitive proof of efficacy. Different reviews may include different trials, use different outcome definitions, and apply different assessments of certainty.
EnerQi maintains a dedicated menopause information category, but individualized assessment remains necessary because menopause-related symptoms may overlap with thyroid disorders, medication effects, sleep disorders, anemia, and other medical conditions.
Bottom line: The 2019 PLOS ONE review showed reduced hot-flush severity and Kupperman Index scores versus placebo. The 2016 Cochrane review found insufficient evidence for firm conclusions. The overall status remains promising but uncertain.
How individualization works
In Traditional Chinese Medicine, individualization is commonly described as syndrome differentiation. The assessment does not classify a formula solely by symptom name. It evaluates patterns across multiple systems and time points.
Relevant assessment domains may include:
- Symptom onset, duration, and daily pattern.
- Sleep quality and circadian timing.
- Appetite, digestion, and bowel function.
- Menstrual or menopausal history.
- Stress response and autonomic symptoms.
- Pain location, quality, and aggravating factors.
- Medication exposure and treatment history.
- Tongue and pulse findings where clinically appropriate.
The formula may be modified as the presentation changes. This creates a research challenge because studies using the same formula do not always represent the same clinical process, and studies using individualized formulas may be difficult to standardize.
EnerQi describes this broader framework through its Root Cause Method, which considers symptom patterns, history, lifestyle, and treatment response rather than relying on a fixed protocol.
Safety and herb-drug interactions
“Natural” does not mean pharmacologically inactive. Chinese herbal formulas can produce adverse effects, alter hepatic metabolism, affect coagulation, and interact with prescription medications.
Safety considerations include:
- Hepatic effects: Some herbal constituents have been associated with elevated aminotransferases or drug-induced liver injury.
- CYP450 interactions: Herbs may inhibit or induce CYP3A4, CYP2C9, CYP2C19, CYP2D6, and related metabolic pathways.
- Anticoagulants and antiplatelets: Formulas containing substances with antiplatelet or anticoagulant activity may increase bleeding risk, particularly with warfarin, aspirin, clopidogrel, or direct oral anticoagulants.
- Chemotherapy: CYP450 and P-glycoprotein modulation may alter exposure to chemotherapy or targeted agents.
- Immunosuppressants: Interaction with tacrolimus, cyclosporine, sirolimus, and related medications may affect therapeutic drug levels.
- Pregnancy and lactation: Safety data are limited for many formulas, and some substances may affect uterine activity, coagulation, endocrine function, or hepatic metabolism.
- Product quality: Contamination, substitution, adulteration, and inconsistent concentration remain documented concerns in herbal-product supply chains.
A complete medication and supplement list should be reviewed before treatment. Oncology, transplant, anticoagulation, pregnancy, and complex autoimmune cases require communication between the Chinese medicine practitioner and the relevant medical specialist.
A licensed and appropriately regulated practitioner should prescribe individualized formulas, document ingredients, monitor tolerance, and modify or discontinue treatment when clinically indicated.
Evidence status summary
| Domain | Evidence signal | Evidence status |
|---|---|---|
| Depression | Lower HAMD scores and adverse-event rates for selected formulas | Promising; low-to-moderate certainty |
| Multiple sclerosis | Improved EDSS, relapse rate, and fatigue when added to conventional care | Promising; moderate-to-very-low GRADE certainty |
| Menopausal hot flushes | Reduced severity and Kupperman scores versus placebo in 2019 review | Conflicting; insufficient for firm conclusions |
| Safety | Adverse events often mild in short trials | Long-term safety and interactions require monitoring |
| Individualized formulas | Clinically central to TCM practice | Difficult to standardize in RCTs |
Clinical conclusion
The available literature identifies several potential Chinese herbal medicine benefits, particularly for depressive symptoms, MS-related disability and fatigue, and menopausal hot-flush severity. The strongest limitation is not the absence of positive findings. It is the limited certainty, inconsistent standardization, short follow-up, geographic concentration, and incomplete safety reporting across many studies.
Chinese herbal medicine is best evaluated as a clinician-supervised intervention within an individualized and coordinated treatment plan. EnerQi Wellness provides information about available treatments, and appointments can be initiated through the contact page.
References
Dang C, Wang Q, Li Q, Xiong Y, Lu Y. 2024. “Chinese herbal medicines for the treatment of depression: a systematic review and network meta-analysis.” Frontiers in Pharmacology.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1295564/fullGuan X et al. 2025. “Efficacy and safety of Chinese herbal medicine for multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.” Frontiers in Pharmacology.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12497746/Li X et al. 2019. “Chinese herbal formulae for the treatment of menopausal hot flushes: a systematic review and meta-analysis.” PLOS ONE.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222383Zhu X et al. 2016. “Chinese herbal medicines for menopausal symptoms.” Cochrane Database of Systematic Reviews.
https://pubmed.ncbi.nlm.nih.gov/26976671/“Herb-drug interactions: a systematic review of Chinese herbs and CYP450 enzymes.”
https://pmc.ncbi.nlm.nih.gov/articles/PMC4464477/Traditional Chinese medicine and pharmacokinetic interactions involving CYP enzymes and transporters. 2022. Frontiers in Pharmacology.
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.974578/fullEnerQi Wellness. “Root Cause Method.”
https://www.enerqiwell.com/blog/the-proven-root-cause-medicine-framework-for-chronic-pain-that-keeps-coming-back-6984c6a3EnerQi Wellness. “Care pathways and services.”
https://www.enerqiwell.com/care